Unknown

Dataset Information

0

De novo expression of circulating biglycan evokes an innate inflammatory tissue response via MyD88/TRIF pathways.


ABSTRACT: Matrix-bound constituents, such as the small leucine-rich proteoglycan biglycan, can act as powerful signaling molecules when released by limited proteolysis of the extracellular matrix or de novo synthesized by macrophages in the circulation and body fluids. Specifically, biglycan acts as an endogenous ligand of innate immunity by directly engaging the Toll-like receptor (TLR)-2 and -4. In this study, we generated a transient transgenic mouse model where biglycan was de novo overproduced by hepatocytes driven by the albumin promoter. Transgenic biglycan was rapidly and abundantly synthesized by hepatocytes and released into the bloodstream. Notably, we found that circulating biglycan accumulated in the kidneys where it caused recruitment of leukocytes infiltrating the renal parenchyma concurrent with abnormal renal levels of chemoattractants CXCL1, CXCL2, CCL2 and CCL5. Using mice deficient in either TLR adapter proteins MyD88 or TRIF we discovered that MyD88 deficiency drastically reduced neutrophil and macrophage infiltration in the kidney, whereas TRIF deficiency decreased T cell infiltrates. Production of CXCL1, CXCL2 and CCL2 required MyD88, whereas the levels of T cell and macrophage attractant CCL5 required TRIF. Thus, we provide robust genetic evidence for circulating biglycan as a powerful pro-inflammatory mediator targeting the renal parenchyma. Furthermore, our results provide the first evidence that biglycan differentially triggers chemoattraction of leukocytes via two independent pathways, both under the control of TLR2/4, utilizing either MyD88 or TRIF adaptor proteins. As aberrant expression of biglycan occurs in several inflammatory diseases, this transient transgenic mouse model could serve as a valuable research tool in investigating the effects of increased biglycan expression in vivo and for the development of therapeutic strategies in the treatment of inflammatory diseases.

SUBMITTER: Zeng-Brouwers J 

PROVIDER: S-EPMC4039567 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

De novo expression of circulating biglycan evokes an innate inflammatory tissue response via MyD88/TRIF pathways.

Zeng-Brouwers Jinyang J   Beckmann Janet J   Nastase Madalina-Viviana MV   Iozzo Renato V RV   Schaefer Liliana L  

Matrix biology : journal of the International Society for Matrix Biology 20131218


Matrix-bound constituents, such as the small leucine-rich proteoglycan biglycan, can act as powerful signaling molecules when released by limited proteolysis of the extracellular matrix or de novo synthesized by macrophages in the circulation and body fluids. Specifically, biglycan acts as an endogenous ligand of innate immunity by directly engaging the Toll-like receptor (TLR)-2 and -4. In this study, we generated a transient transgenic mouse model where biglycan was de novo overproduced by hep  ...[more]

Similar Datasets

| S-EPMC4537368 | biostudies-literature
| S-EPMC3494976 | biostudies-literature
| S-EPMC9446533 | biostudies-literature
| S-EPMC5969770 | biostudies-literature
| S-EPMC4469326 | biostudies-literature
| S-EPMC4685476 | biostudies-literature
| S-EPMC6764925 | biostudies-literature
| S-ECPF-GEOD-49035 | biostudies-other
| S-EPMC5680545 | biostudies-literature
| S-EPMC9761135 | biostudies-literature